While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center, wrote that the promise of incorporating new treatments and predictive ...

GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Source Reference: Satyal U, et al "Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates" JCO Precis Oncol 2024; DOI: 10.1200/PO.

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a new editorial.

Currently, patients with bladder cancer are monitored for cancer recurrence or progression by periodic cystoscopy and urine cytology, the frequency of which varies depending on the risk factors ...

The promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment every time offers a bright future for bladder cancer patients.